Cytogenetic and molecular genetic changes in malignant mesothelioma.

[1]  R. Kratzke,et al.  Molecular pathways in malignant pleural mesothelioma. , 2006, Cancer letters.

[2]  H. Wikman,et al.  Regulation of the G1/S phase of the cell cycle and alterations in the RB pathway in human lung cancer , 2006, Expert review of anticancer therapy.

[3]  A. Olshen,et al.  Global gene expression profiling of pleural mesotheliomas: overexpression of aurora kinases and P16/CDKN2A deletion as prognostic factors and critical evaluation of microarray-based prognostic prediction. , 2006, Cancer research.

[4]  S. Knuutila,et al.  Spindle cell tumours of the pleura: a clinical, histological and comparative genomic hybridization analysis of 14 cases , 2006, Virchows Archiv.

[5]  Y. Kobashi,et al.  Clinicopathological analysis of lung cancer resembling malignant pleural mesothelioma , 2005, Respirology.

[6]  Hongtae Kim,et al.  The Phosphorylation status of merlin is important for regulating the Ras-ERK pathway. , 2005, Molecules and cells.

[7]  K. Dahlman-Wright,et al.  Molecular characterization of tumour heterogeneity and malignant mesothelioma cell differentiation by gene profiling , 2005, The Journal of pathology.

[8]  T. Papp,et al.  Mutational analysis of 9 different tumour-associated genes in human malignant mesothelioma cell lines. , 2005, Oncology reports.

[9]  K. Müller,et al.  Chromosomal alterations in early stages of malignant mesotheliomas , 2005, Virchows Archiv.

[10]  M. Ladanyi.  Implications of P16/CDKN2A deletion in pleural mesotheliomas. , 2005, Lung cancer.

[11]  Laurie Kazan-Allen,et al.  Asbestos and mesothelioma: worldwide trends. , 2005, Lung cancer.

[12]  R. Jensen,et al.  Validation of Genomics-Based Prognostic Tests in Malignant Pleural Mesothelioma , 2005, Clinical Cancer Research.

[13]  David J Sugarbaker,et al.  Tumorigenesis and Neoplastic Progression Identification of Novel Candidate Oncogenes and Tumor Suppressors in Malignant Pleural Mesothelioma Using Large-Scale Transcriptional Profiling , 2005 .

[14]  M. Neri,et al.  SV40 enhances the risk of malignant mesothelioma among people exposed to asbestos: a molecular epidemiologic case-control study. , 2005, Cancer research.

[15]  J. I. Phillips,et al.  Evidence against a role for SV40 in human mesothelioma. , 2005, Cancer research.

[16]  H. Pass,et al.  Identification of intelectin overexpression in malignant pleural mesothelioma by serial analysis of gene expression (SAGE). , 2005, Lung cancer.

[17]  S. Jhanwar,et al.  The NF2 Tumor Suppressor Gene Product, Merlin, Inhibits Cell Proliferation and Cell Cycle Progression by Repressing Cyclin D1 Expression , 2005, Molecular and Cellular Biology.

[18]  S. Bodur,et al.  Analysis of chromosomes 9 and 11 aneuploidy frequency in pleural effusions of patients with and without malignancy: By interphase FISH technique , 2005, Cancer biology & therapy.

[19]  G. Serio,et al.  Familial pleural mesothelioma with environmental asbestos exposure: losses of DNA sequences by comparative genomic hybridization (CGH) , 2004, Histopathology.

[20]  A. Nicholson,et al.  L1CAM, INP10, P-cadherin, tPA and ITGB4 over-expression in malignant pleural mesotheliomas revealed by combined use of cDNA and tissue microarray. , 2004, Carcinogenesis.

[21]  Chuong D. Hoang,et al.  Gene expression profiling identifies matriptase overexpression in malignant mesothelioma. , 2004, Chest.

[22]  C. Bianchi,et al.  Familial mesothelioma of the pleura--a report of 40 cases. , 2004, Industrial health.

[23]  Sorin Draghici,et al.  Gene Expression Profiles Predict Survival and Progression of Pleural Mesothelioma , 2004, Clinical Cancer Research.

[24]  F. Galateau-Sallé,et al.  Cell protection, resistance and invasiveness of two malignant mesotheliomas as assessed by 10K-microarray. , 2004, Biochimica et biophysica acta.

[25]  Jonathan Chernoff,et al.  NF2: The wizardry of merlin , 2003, Genes, chromosomes & cancer.

[26]  S. Bonassi,et al.  Implementation of a molecular epidemiology approach to human pleural malignant mesothelioma. , 2003, Mutation research.

[27]  N. Sneige,et al.  Detection of numerical aberrations of chromosomes 7 and 9 in cytologic specimens of pleural malignant mesothelioma , 2003, Cancer.

[28]  Sunil Singhal,et al.  Gene expression profiling of malignant mesothelioma. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[29]  M. Martinelli,et al.  Microarray analysis and RNA silencing link fra-1 to cd44 and c-met expression in mesothelioma. , 2003, Cancer research.

[30]  Anne Janin,et al.  Hemizygosity of Nf2 is associated with increased susceptibility to asbestos-induced peritoneal tumours , 2003, Oncogene.

[31]  M. Ladanyi,et al.  Homozygous deletion of CDKN2A and codeletion of the methylthioadenosine phosphorylase gene in the majority of pleural mesotheliomas. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[32]  K. Müller,et al.  Mutational analysis of the nf2 tumour suppressor gene in three subtypes of primary human malignant mesotheliomas. , 2003, International journal of oncology.

[33]  K. Uematsu,et al.  Genomic alterations in human mesothelioma including high resolution mapping of common regions of DNA loss in chromosome arm 6q. , 2003, Anticancer research.

[34]  M. Giovannini,et al.  NF2 deficiency promotes tumorigenesis and metastasis by destabilizing adherens junctions. , 2003, Genes & development.

[35]  J. Blumenstock,et al.  Using gene expression ratios to predict outcome among patients with mesothelioma. , 2003, Journal of the National Cancer Institute.

[36]  M. Ladanyi,et al.  The use of CDKN2A deletion as a diagnostic marker for malignant mesothelioma in body cavity effusions , 2002, Cancer.

[37]  R. Kratzke,et al.  Inactivation of p16INK4a expression in malignant mesothelioma by methylation. , 2002, Lung cancer.

[38]  G. Serio,et al.  A cluster of familial malignant mesothelioma with del(9p) as the sole chromosomal anomaly. , 2002, Cancer genetics and cytogenetics.

[39]  L. Pylkkänen,et al.  Concurrent LOH at multiple loci in human malignant mesothelioma with preferential loss of NF2 gene region. , 2002, Oncology reports.

[40]  S. Ramaswamy,et al.  Translation of microarray data into clinically relevant cancer diagnostic tests using gene expression ratios in lung cancer and mesothelioma. , 2002, Cancer research.

[41]  U. Brinck,et al.  The Potential Value of Comparative Genomic Hybridization Analysis in Effusion—and Fine Needle Aspiration Cytology , 2002, Modern Pathology.

[42]  L. Pitts,et al.  Neurofibromatosis 2 and malignant mesothelioma. , 2002, Neurology.

[43]  K. Müller,et al.  Molecular cytogenetic differences between histological subtypes of malignant mesotheliomas: DNA cytometry and comparative genomic hybridization of 90 cases , 2002, The Journal of pathology.

[44]  G. Gordon,et al.  Alterations of the p16(INK4) locus in human malignant mesothelial tumors. , 2002, Carcinogenesis.

[45]  K. Yokoyama,et al.  Assessment of the mutations of p53 suppressor gene and Ha- and Ki-ras oncogenes in malignant mesothelioma in relation to asbestos exposure: a study of 12 American patients. , 2002, Industrial health.

[46]  F. Nardi,et al.  A one-generation cluster of malignant mesothelioma within a family reveals exposure to asbestos-contaminated jute bags in Naples, Italy , 2002, European Journal of Epidemiology.

[47]  J. Testa,et al.  The pathogenesis of mesothelioma. , 2002, Seminars in oncology.

[48]  H. Kindler,et al.  New approaches for mesothelioma: biologics, vaccines, gene therapy, and other novel agents. , 2002, Seminars in oncology.

[49]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: clear cell sarcoma (malignant melanoma of soft parts). , 2001, Cancer genetics and cytogenetics.

[50]  A. Sandberg,et al.  Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors. Mesothelioma. , 2001, Cancer genetics and cytogenetics.

[51]  A. Marrogi,et al.  Paradoxical effects of platelet-derived growth factor-A overexpression in malignant mesothelioma. Antiproliferative effects in vitro and tumorigenic stimulation in vivo. , 2001, American journal of respiratory cell and molecular biology.

[52]  S. Knuutila,et al.  DNA copy number changes in familial malignant mesothelioma. , 2001, Cancer genetics and cytogenetics.

[53]  P. Vineis,et al.  Misconceptions about the use of genetic tests in populations , 2001, The Lancet.

[54]  S. Knuutila,et al.  Gene expression profiling of malignant mesothelioma cell lines: cDNA array study , 2001, International journal of cancer.

[55]  J. Testa,et al.  Genetic-susceptibility factor and malignant mesothelioma in the Cappadocian region of Turkey , 2001, The Lancet.

[56]  J. Testa,et al.  SV40 and cell cycle perturbations in malignant mesothelioma. , 2001, Seminars in cancer biology.

[57]  D. Weiss,et al.  Mutational analysis of N-ras, p53, p16INK4a, p14ARF and CDK4 genes in primary human malignant mesotheliomas. , 2001, International journal of oncology.

[58]  A. Musk,et al.  p53 autoantibodies in patients with malignant mesothelioma: stability through disease progression , 2001, British Journal of Cancer.

[59]  X. Sun,et al.  Upregulation of 9 genes, including that for thioredoxin, during epithelial differentiation of mesothelioma cells. , 2000, Differentiation; research in biological diversity.

[60]  G. Leikauf,et al.  Differential gene expression in mesothelioma , 2000, FEBS letters.

[61]  K. Müller,et al.  Patterns of chromosomal imbalances in benign solitary fibrous tumours of the pleura , 2000, Virchows Archiv.

[62]  S. Jhanwar,et al.  Loss of heterozygosity analysis of 13q and 14q in human malignant mesothelioma , 2000, Genes, chromosomes & cancer.

[63]  Y. Liu,et al.  Analysis of K-ras and p53 mutations in mesotheliomas from humans and rats exposed to asbestos. , 2000, Mutation research.

[64]  J. Kere,et al.  Deletions at 14q in malignant mesothelioma detected by microsatellite marker analysis , 1999, British Journal of Cancer.

[65]  G. Hillerdal.  Mesothelioma: cases associated with non-occupational and low dose exposures. , 1999, Occupational and environmental medicine.

[66]  J. Cheng,et al.  Frequent mutations of NF2 and allelic loss from chromosome band 22q12 in malignant mesothelioma: Evidence for a two‐hit mechanism of NF2 inactivation , 1999, Genes, chromosomes & cancer.

[67]  F Levi,et al.  The European mesothelioma epidemic , 1999, British Journal of Cancer.

[68]  S. Jhanwar,et al.  Comparative genomic hybridization and loss of heterozygosity analyses identify a common region of deletion at 15q11.1-15 in human malignant mesothelioma. , 1999, Cancer research.

[69]  V. Rusch,et al.  A multi-institutional study confirms the presence and expression of simian virus 40 in human malignant mesotheliomas. , 1998, Cancer research.

[70]  F. Nardi,et al.  Familial pleural malignant mesothelioma: clustering in three sisters and one cousin. , 1998, Cancer letters.

[71]  M. Giovannini,et al.  Heterogeneity of mesothelioma cell lines as defined by altered genomic structure and expression of the NF2 gene , 1998, International journal of cancer.

[72]  N. Sasaki,et al.  Two familial mesothelioma cases with high concentrations of soluble cytokeratin 19 fragment in pleural fluid. , 1998, Internal medicine.

[73]  T. H. van der Kwast,et al.  The gene for the cyclin‐dependent‐kinase‐4 inhibitor, CDKN2A, is preferentially deleted in malignant mesothelioma , 1998, International journal of cancer.

[74]  F P Perera,et al.  Environment and cancer: who are susceptible? , 1997, Science.

[75]  S. Jhanwar,et al.  Multiple regions of allelic loss from chromosome arm 6q in malignant mesothelioma. , 1997, Cancer research.

[76]  B. Mossman,et al.  Asbestos causes stimulation of the extracellular signal-regulated kinase 1 mitogen-activated protein kinase cascade after phosphorylation of the epidermal growth factor receptor. , 1996, Cancer research.

[77]  S. Jhanwar,et al.  Loss of heterozygosity analysis defines a critical region in chromosome 1p22 commonly deleted in human malignant mesothelioma. , 1996, Cancer research.

[78]  K. Pelin,et al.  Gains and losses of DNA sequences in malignant mesothelioma by comparative genomic hybridization. , 1996, Cancer genetics and cytogenetics.

[79]  T. H. van der Kwast,et al.  EXPRESSION OF PLATELET‐DERIVED GROWTH FACTOR (PDGF) AND PDGF RECEPTORS IN HUMAN MALIGNANT MESOTHELIOMA IN VITRO AND IN VIVO , 1996, The Journal of pathology.

[80]  S. Jhanwar,et al.  High frequency of inactivating mutations in the neurofibromatosis type 2 gene (NF2) in primary malignant mesotheliomas. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[81]  M. Huncharek.  Genetic factors in the aetiology of malignant mesothelioma. , 1995, European journal of cancer.

[82]  J. Fletcher,et al.  Codeletion of p15 and p16 in primary malignant mesothelioma. , 1995, Oncogene.

[83]  J. Minna,et al.  Neurofibromatosis type 2 (NF2) gene is somatically mutated in mesothelioma but not in lung cancer. , 1995, Cancer research.

[84]  O. Olopade,et al.  p16 alterations and deletion mapping of 9p21-p22 in malignant mesothelioma. , 1994, Cancer research.

[85]  W. M. Linehan,et al.  Loss of heterozygosity on the short arm of chromosome 3 in mesothelioma cell lines and solid tumors , 1994, Genes, chromosomes & cancer.

[86]  J. Cheng,et al.  Deletion mapping of the short arm of chromosome 3 in human malignant mesothelioma , 1994, Genes, chromosomes & cancer.

[87]  V. Skaug,et al.  Karyotypic changes in the preclinical and subsequent stages of malignant mesothelioma: a case report. , 1993, Cancer genetics and cytogenetics.

[88]  J. Cheng,et al.  Homozygous deletions within 9p21-p22 identify a small critical region of chromosomal loss in human malignant mesotheliomas. , 1993, Cancer research.

[89]  S. Jhanwar,et al.  Recurrent deletions of specific chromosomal sites in 1p, 3p, 6q, and 9p in human malignant mesothelioma. , 1993, Cancer research.

[90]  O. Garson,et al.  Molecular deletion of 9p sequences in non‐small cell lung cancer and malignant mesothelioma , 1993, Genes, chromosomes & cancer.

[91]  S. Knuutila,et al.  Comparison of DNA and karyotype ploidy in malignant mesothelioma. , 1992, Cancer genetics and cytogenetics.

[92]  R. Metcalf,et al.  p53 and Kirsten-ras mutations in human mesothelioma cell lines. , 1992, Cancer research.

[93]  F. Li,et al.  del(6q) as a possible primary change in malignant mesothelioma. , 1992, Cancer genetics and cytogenetics.

[94]  J. Kere,et al.  Abnormalities of chromosomes 7 and 22 in human malignant pleural mesothelioma: Correlation between southern blot and cytogenetic analyses , 1992, Genes, chromosomes & cancer.

[95]  T. H. van der Kwast,et al.  Cytogenetic analysis of malignant mesothelioma. , 1990, Cancer genetics and cytogenetics.

[96]  A. Sandberg,et al.  Chromosome 3 and 12p rearranged in a well-differentiated peritoneal mesothelioma. , 1990, Cancer genetics and cytogenetics.

[97]  C. Harris,et al.  Asbestos-related malignant mesothelioma: growth, cytology, tumorigenicity and consistent chromosome findings in cell lines from five patients. , 1990, Carcinogenesis.

[98]  J. Testa,et al.  Recurring loss involving chromosomes 1, 3, and 22 in malignant mesothelioma: Possible sites of tumor suppressor genes , 1989, Genes, chromosomes & cancer.

[99]  S. Knuutila,et al.  Chromosomal abnormalities and their correlations with asbestos exposure and survival in patients with mesothelioma. , 1989, British Journal of Cancer.

[100]  S. Knuutila,et al.  Nonrandom chromosomal abnormalities in malignant pleural mesothelioma. , 1988, Cancer genetics and cytogenetics.

[101]  E. Gabrielson,et al.  Comparison of production of transforming growth factor-beta and platelet-derived growth factor by normal human mesothelial cells and mesothelioma cell lines. , 1987, Cancer research.

[102]  R. Stahel,et al.  Chromosome changes in malignant mesothelioma. , 1986, Cancer genetics and cytogenetics.

[103]  J. Wagner,et al.  Diffuse Pleural Mesothelioma and Asbestos Exposure in the North Western Cape Province , 1960, British journal of industrial medicine.

[104]  G. Gordon,et al.  Functional analysis of c-Met/hepatocyte growth factor pathway in malignant pleural mesothelioma. , 2006, Cancer research.

[105]  L. Pylkkänen,et al.  Reduced Fhit protein expression in human malignant mesothelioma , 2004, Virchows Archiv.

[106]  H. Norppa,et al.  DNA damage in bronchial epithelial and mesothelial cells with and without associated crocidolite asbestos fibers , 2004, Environmental and molecular mutagenesis.

[107]  B. Rihn,et al.  Microdissection, mRNA amplification and microarray: a study of pleural mesothelial and malignant mesothelioma cells. , 2004, Biochimie.

[108]  F. McCormick,et al.  A comparison analysis of anti-tumor efficacy of adenoviral gene replacement therapy (p14ARF and p16INK4A) in human mesothelioma cells. , 2003, Anticancer research.

[109]  I. Poser,et al.  Interphase fish analysis of cell cycle genes in asbestos-treated human mesothelial cells (HMC), SV40-transformed HMC (MeT-5A) and mesothelioma cells (COLO). , 2002, Cellular and molecular biology.

[110]  J. Minna,et al.  Deletions of chromosome 4 at multiple sites are frequent in malignant mesothelioma and small cell lung carcinoma. , 1999, Clinical cancer research : an official journal of the American Association for Cancer Research.

[111]  S. Knuutila,et al.  Comparative genomic hybridization study on pooled DNAs from tumors of one clinical-pathological entity. , 1998, Cancer genetics and cytogenetics.

[112]  F. Kitamura,et al.  Assessment of mutations of Ha- and Ki-ras oncogenes and the p53 suppressor gene in seven malignant mesothelioma patients exposed to asbestos--PCR-SSCP and sequencing analyses of paraffin-embedded primary tumors. , 1998, Industrial health.

[113]  S. Knuutila,et al.  Comparison of DNA copy number changes in malignant mesothelioma, adenocarcinoma and large-cell anaplastic carcinoma of the lung. , 1998, British Journal of Cancer.

[114]  G. Rechavi,et al.  Absence of p53 mutations in malignant mesotheliomas. , 1997, American journal of respiratory cell and molecular biology.

[115]  K. Hemminki,et al.  Mutations, tissue accumulations, and serum levels of p53 in patients with occupational cancers from asbestos and silica exposure , 1997, Environmental and molecular mutagenesis.

[116]  S. Knuutila,et al.  Recurrent DNA copy number changes in 1q, 4q, 6q, 9p, 13q, 14q and 22q detected by comparative genomic hybridization in malignant mesothelioma. , 1997, British Journal of Cancer.

[117]  H. Pass,et al.  In vitro and in vivo studies of mesothelioma , 1996, Journal of cellular biochemistry. Supplement.

[118]  D. Fitzpatrick,et al.  Transforming growth factor-beta: antisense RNA-mediated inhibition affects anchorage-independent growth, tumorigenicity and tumor-infiltrating T-cells in malignant mesothelioma. , 1994, Growth factors.

[119]  S. Knuutila,et al.  Malignant mesothelioma: clinical characteristics, asbestos mineralogy and chromosomal abnormalities of 41 patients. , 1992, European journal of cancer.

[120]  J. DiPaolo,et al.  Nonrandom chromosome alterations in human malignant mesothelioma. , 1988, Cancer research.